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ABSTRACT
Introduction: Lung fibrosis is a progressive, fatal disease that is characterized by increasing fibrob-
lasts proliferation and extracellular matrix precipitation. Studies have shown that cyclooxygenase-
2 (Cox-2) could play a crucial role in the pathogenesis of lung fibrosis. In the current study, the
effect of thalidomide on bleomycin-induced pulmonary fibrosis was qualitatively studied in a lab-
oratory animal model.Methods: Thirty-two adult male C57BL/6 mice were randomly assigned to
the following four groups: Group one received 2 mg bleomycin, group two received bleomycin
in addition to 4 mg of thalidomide; group three received 4 mg of thalidomide, and Group 4 re-
ceived 0.1mg of 0.5% carboxymethyl cellulose (CMC) via intraperitoneal (IP) administration. Finally,
the expression of Cox-2 protein and the percentage of contact points of alveolar spaces and pul-
monary connective tissue were determined. Results: Our results showed that in the Bleo + Thal
group compared to the Bleo group, the percentage of contact points of pulmonary connective tis-
sue decreased significantly (P<0.001), while the percentage of contact points among the alveolar
spaces increased significantly (P = 0.01). Also, immunohistochemical studies have demonstrated
the number of Cox-2+ cells in the volume unit in the Bleo + Thal group decreased significantly in
comparison with the group that received only Bleo (P = 0.012). Conclusion: In conclusion, these
results suggest thalidomide could alleviate the bleomycin-induced lung fibrosis and decreases the
expression of Cox-2 protein.
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INTRODUCTION
Lung fibrosis is the end stage of a diverse group of
pulmonary disorders known as interstitial lung dis-
eases. The most common disease among this group
is idiopathic pulmonary fibrosis (IPF) 1. IPF is a
chronic progressive disease with unknown pathogen-
esis, which has the worst prognosis among the inter-
stitial lung diseases with the mean survival time of
2–4 years after diagnosis, and the prevalence rate of
20 and 13 cases per 100,000 male and female respec-
tively 2. It was previously assumed that the pathogen-
esis of IPF is related to chronic pulmonary inflamma-
tion 3. According to this theory, unknown stimula-
tors lead to chronic inflammation, which causes fibro-
sis 3. Because interstitial inflammation could play a
crucial role in pulmonary fibrosis, anti-inflammatory
adrenocorticosteroids have been widely used for IPF
patients. However, anti-inflammatory treatments
were not so successful in treating IPF 4. It seems that
other factors may contribute to this process. Recent
studies have shown that tissue remodeling after ep-
ithelial injury is another important process in IPF
pathogenesis 5. Moreover, pulmonary fibrosis may be
induced by various factors, including herpes virus,
silica, asbestos, butylated hydroxytoluene, radiation,
and bleomycin. Bleomycin is indeed a chemother-
apy agent which is used in cancer treatment, and one
of its common adverse effects is pulmonary fibrosis.
Today, this medication is used to induce fibrosis in
animal models 6,7. Furthermore, studies have shown
that cyclooxygenase-2 (Cox-2) is an importantmarker
involved in the pulmonary fibrosis process. Cox-2
is the catalyst in the biosynthesis of prostaglandins
from arachidonic acid 8. In addition, the Cox-2 path-
way is clinically important in the pathogenesis of pul-
monary fibrosis. Thus, factors influencing Cox-2 ex-
pression might affect the process of pulmonary fibro-
sis. In this regard, studies have demonstrated that the
non-steroidal anti-inflammatory drugs (NSAIDs)—
which are commonly used in reducing inflammation,
pain, and fever may alter the expression of COX2
protein. In 1991, two distinct types of Cox protein,
namely Cox-1 and Cox-2, were reported, while Cox-
3 has recently been discovered 9. Cox-1 is continu-
ously expressed in many tissues, while Cox-2 is ex-
pressed when the tissue is stimulated by inflamma-
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tion or mitogen stimulators 10. It has been demon-
strated that inflammation and Cox protein could play
crucial roles in the development of pulmonary fibrosis
and could be considered as markers of the condition.
Therefore, researchers have evaluated the use of anti-
inflammatory agents in inhibiting pulmonary fibro-
sis. Furthermore, previous studies have shown that
thalidomide can attenuate inflammation 11. Thalido-
mide, a derivative of glutamic acid, was first intro-
duced for the treatment of nausea in pregnantwomen.
Due to its teratogenic effects, the drug was with-
drawn from the pharmaceutical market in 1960. A
few years later, it was confirmed that the drug’s ad-
verse effect is secondary to its inhibitory effect on an-
giogenesis in developing fetal limb bud 12. Fujita et
al. reported the important function of thalidomide
in the treatment of cancer patients through modula-
tion of the Cox pathway 13. Moreover, several clini-
cal studies have confirmed the efficiency of thalido-
mide and its analogs in various diseases including
rheumatoid arthritis 14,15, Castleman’s disease 16, and
Crohn’s disease 17. Moreover, thalidomide has been
used in the treatment of some malignancies includ-
ing AIDS-associated Kaposi sarcoma 18, renal cell car-
cinoma 19, and myelodysplastic syndrome 20. It is
worth to mention that different fibroproliferative dis-
eases have common pathogenesis processes 21. Based
on the evidence provided by previous studies on
thalidomide 22–24, in the current study, the effect of
thalidomide on the expression of Cox-2 protein in
bleomycin-induced pulmonary fibrosis was investi-
gated in C57BL/6 mice.
METHODS
Animals and ethics
Thirty-two male C57BL/6 mice with the average
weight of 20–25 g and aged 6-8 weeks were studied.
The mice were obtained from the Pasteur Institute
(Tehran, Iran). This study was approved by the Ethics
Committee of Kurdistan University of Medical Sci-
ences (IR.MUK.REC.1395.382).
Groups and treatments
In this experimental study, adult male C57BL/6 mice
(Purchased from Pasteur Institute of Iran; Tehran)
weighing 20–25 g on average at the age of 6–8 weeks
were randomly allocated to four groups, each includ-
ing eight mice. Group one (Bleo): 2 mg of bleomycin
sulfate (Nippon Kayaku, Tokyo, Japan) were dissolved
in 0.1 ml carboxymethyl cellulose (CMC) (Sigma
Corp. St. Louis, Missouri, USA) 0.5%, and then ad-
ministered via intraperitoneal injection on Days 1, 8,
and 15. Group two (Bleo+Thal) received bleomycin as
was mentioned for the Bleo group plus 4 mg thalido-
mide (Sigma Corp. St. Louis, Missouri, USA) dis-
solved in 0.1 mL CMC 0.5% via intraperitoneal injec-
tion five times a week for one month. Group three
(Thal) received 4 mg thalidomide (Sigma, USA) dis-
solved in 0.1 mL CMC 0.5% via intraperitoneal in-
jection five times a week for one month, and Group
four (CMC) received 0.1 mL CMC 0.5% via intraperi-
toneal injection five times a week for one month.
At the end of the experiment, the animals were sac-
rificed using an overdose of ketamine. The thorax
was opened, the lungs were removed, and after be-
ing washed with PBS, the lungs were placed in for-
malin 10%. Then, the tissues were dehydrated at dif-
ferent levels, molded, and sections with 6-μm thick-
ness were prepared. The samples were then stained
using hematoxylin (Merck KGaA, Darmstadt, Ger-
many) and eosin (Sigma-Aldrich Corp. St. Louis,
Missouri, USA) (H& E) to investigate the histological
changes, and stained by Masson’s trichrome (Sigma
Corp. St. Louis, Missouri, USA) to evaluate the col-
lagen deposition within the lung parenchyma under
lightmicroscopy (Carl ZeissMicroscopyGmbH, Jena,
Germany). Morphological changes of the pulmonary
tissue were evaluated. Moreover, the percentages of
alveolar spaces and pulmonary connective tissue were
determined by point-counting methods per volume
unit. In this method, for each group, 15 fields of 15
sections were examined with 40X magnification.
Immunohistochemical analysis
The expression of Cox-2 protein was evaluated by im-
munohistochemistry. Sections with the thickness of
6 μm were prepared by sectioning tissue blocks em-
bedded in solid paraffin. The sections were mounted
on silanized slides (Sigma, USA).The slides were then
placed in an oven at 60 ºC and deparaffinized and
rehydrated in three steps. After that, antigen re-
trieval was performed by applying citrate buffer so-
lution for 17 minutes. Endogenous peroxidase ac-
tivity was blocked by adding 3% H2O2 for 10 min-
utes. To neutralize extra proteins, 2% bovine serum
albumin solution (Pars Tos, Iran) was used. The so-
lution obtained was then incubated overnight with
rabbit-specific primary antibody against Cox-2 (Ab-
cam, Cambridge, UK) at 4 ºC.Then, the samples were
rinsed, and incubated with rabbit-specific secondary
antibody against Cox-2 (Abcam, England) was added.
After rinsing, diaminobenzidine (DAB) (Roche, Ger-
many) was added, and the samples were kept in dark-
ness for 10 minutes. The nucleus staining was per-
formed by using hematoxylin, and the samples were
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mounted on slides. Cox-2+ cells were counted us-
ing Motic software (Motic Image Plus 2.0, Richmond,
Canada). The software calibration was performed us-
ing a scaled slide to measure in micrometers, and the
number of Cox-2 expressing cells was determined in
15 fields of 15 sections 25.
Statistical analysis
The experimental results are presented as mean 
Standard Deviation (SD). Following the assurance of
normal distribution of data, data significance and
correlations was estimated using one-way analysis of
variance (ANOVA) with the Newman–Keuls posthoc
test in GraphPad Prism 5.0 (GraphPad Software, Inc.,
San Diego, CA), and also in all the tests, P<0.05 was
considered statistically significant.
RESULTS
Histopathological and immunohistochemi-
cal qualitative results
The qualitative results obtained from the histopatho-
logical evaluation of the pulmonary tissue demon-
strated that the level of inflammation and fibrosis,
the deposition of collagen fibers, and the expression
of Cox-2 protein were different across various ex-
perimental fibrotic changes were observed. In addi-
tion, the infiltration of inflammatory cells in alveo-
lar spaces, disorganization of the alveolar structure,
impairment of alveolar walls, development of cys-
tic changes in alveoli, and the amount of connective
tissue also increased (Figure 1A). Collagen deposi-
tion in the interstitial connective tissue was observed
as blue fibers in the Masson’s trichrome staining
(Figure 1B). According to the results obtained from
immunohistochemical studies,Cox-2-expressing cells
were present between the epithelial cells of the alveoli
and the connective tissue (Figure 1C).
Histological and Immunohistochemical analysis on
the lung tissue in Thal group shows that the lung tis-
sue alveoli have a normal appearance. There is no evi-
dence of the congestion and inflammatory cells. Also,
there is no evidence of interstitial tissue remodeling
(Figure 2A). The results of photomicrographs from
Masson’s trichrome staining showed areas with lower
level collagen (Figure 2B).Cox-2 immunohistochem-
istry (anti- Cox-2) shows that Cox-2+ cells are rarely
observed (Figure 2C).
However, the Bleo+Thal group showed a relative re-
duction in the number of inflammatory cells, thinner
alveolar walls, and a better organization of the alve-
olar structure. Fewer changes associated with alveo-
lar impairment were observed. Moreover, remodel-
ing in connective tissue is less visible than group one.
Also, both type 1 and type 2 pneumocyte cells can be
seen (mostly type 2) in epithelial cells of the alveoli
(Figure 3A).The level of collagen fiber deposition rel-
atively reduced (Figure 3B), and immunohistochemi-
cal studies showed the expression of Cox-2 among the
connective tissue (Figure 3C).
On the other hand, results obtained from tissue
sections stained with H&E (Figure 4A), Masson’s
trichrome (Figure 4B) and immunohistochemistry
(Figure 4C) in the CMC group (IV) showing no sig-
nificant change in the lung tissue and collagen lev-
els. No evidence of increased fibrosis and Cox-2 pos-
itive cells in the connective tissue epithelium were
observed. Furthermore, the changes were similar to
those demonstrated in group two.
Quantitative Morphometry
Quantitative results related to the pulmonary alveoli
and connective tissue of the mice in different groups
were obtained by the morphometric method, and the
percentages of contact points of alveolar spaces and
pulmonary connective tissue for the four groups were
determined. The mean values for the contact point
of alveolar spaces in the volume unit were 39.20% 
8.11, 52.77%  3.39, 59.17%  7.97, and 64.15% 
5.42 for the Bleo, Bleo+Thal, Thal, and CMC groups,
respectively. The results indicate an increase in the
alveolar spaces in the Bleo+Thal group compared to
the Bleo group. Statistical analysis showed that the
groups differed significantly from each other regard-
ing the percentage of the alveolar spaces (P<0.001).
However, in this regard, comparison of the Thal and
Bleo+Thal groups (P= 0.1) and the Thal and CMC
groups (P=0.04) did not show statistically significant
differences. The mean percentage of contact points
of connective tissue in the volume unit determined
for the Bleo, Bleo+Thal, Thal, and CMC groups were
59.59%  8.87, 47.22%  3.39, 40.82%  7.97, and
35.84%  5.43, respectively. This result demon-
strates an increase in the amount of connective tis-
sue in the Bleo group compared to the Bleo+Thal
group. The groups differed significantly in this respect
(P<0.001). Nevertheless, comparison of the Thal and
Bleo+Thal groups (P= 0.1) and the Thal and CMC
groups (P=0.04) did not show significant differences.
Furthermore, the mean number of Cox-2+cells in the
Bleo, Bleo+Thal, Thal, and CMC groups were 11.08
 0.6, 7.54  0.6, 2.36  0.32, and 3.14  0.48, re-
spectively. According to the results obtained from the
statistical analyses, the number of Cox-2+cells in the
Bleo group compared toThal group were significantly
increased (P=0.006). Similarly, a significant increase
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Figure 1: Histological and immunohistochemical evaluation of the lung tissue in Bleo group one. (A) (H&E
staining). The images demonstrate evidence of interstitial the lung tissue and fibroblasts cells proliferation (ar-
rowheads), as well as the inflammatory cell infiltration (arrows). Also, the number of lung tissue alveolar spaces
have a significant decrease when compared control group (open arrowheads). (B) Image of lung tissue obtained
from Masson’s trichrome staining. The blue color in the image indicates areas containing collage deposition that
in the form of thick and coarse bands is appearance (arrows). (C) (IHC staining) shows the numerous cells with
brown cytoplasm that expressing Cox-2 protein. Often of Cox-2+ cells observed in the fibrotic region (interstitial
connective tissue) through alveolar epithelial cells (arrows) and rarely were found between alveolar epithelium
(arrowheads). The images were acquired at the 40X magnification.
in the number of Cox-2+cells was detected in the
Bleo group compared to the CMC group (P=0.007).
The number of Cox-2+cells was significantly reduced
in the Bleo+Thal group when compared to the Bleo
group (P=0.012). However, theThal andCMCgroups
were not significantly different from each other in this
regard (Figure 5).
DISCUSSION
In the present study, the effect of thalidomide on
the lung fibrosis, induced by intraperitoneal admin-
istration of bleomycin in mice, was investigated.
The qualitative and quantitative examinations on the
lung tissue of different groups were performed using
histomorphometric and immunohistochemical ap-
proaches. The histological results of the Bleo group
showed an impairment in alveolar walls, develop-
ment of cystic modifications, increased connective
tissue, and deposition of higher amounts of collagen
fibers in the pulmonary connective tissue vis-à-vis the
Bleo+Thal group. In this study, a significant reduction
of connective tissue and a significant increase in alve-
olar spaces in the bleomycin thalidomide group com-
pared to the bleomycin group suggested a decrease in
fibrosis following thalidomide treatment.
As shown by the immunohistochemical studies, the
number of Cox-2-expressing cells in the Bleo group
increased compared to the Bleo+Thal group. Accord-
ing to morphometric studies, the percentage of con-
tact points of alveolar spaces in the volume unit in the
Bleo+Thal group was significantly higher than that
in the Bleo group (P<0.001). In addition, the per-
centage of contact points of connective tissue in the
volume unit in the Bleo group increased significantly
when compared with the Bleo+Thal group (P<0.001).
Increased connective tissue and decreased alveolar
2977
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Figure 2: Histological and Immunohistochemical analysis of the lung tissue in Thal group two.(A) The lung
alveolar tissues have a normal appearance, and no evidence of the congestion and inflammatory cells was ob-
served. Also, there was no evidence of interstitial tissue remodeling. (B) The results of photomicrographs from
Masson’s trichrome staining. The area involved collagen fibrils, in this regard, with reduced levels of collagen.
(C)Cox-2 immunohistochemistry (anti-Cox-2) shows that the number of Cox-2+ cells is rarely observed.
spaces in the Bleo group indicate pulmonary fibrosis
induced by bleomycin. Moreover, according to the re-
sults of the current study, administration of thalido-
mide in the Belo + Thal group led to a statistically
significant increase in connective tissue and an in-
crease in the alveolar spaces compared to the Bleo
group. These results indicated the alleviation of fibro-
sis following administration of thalidomide. More-
over, Tabeta et al. (2007) showed that thalidomide
has an inhibitory effect on bleomycin-induced pul-
monary fibrosis in laboratory mice 23. They employed
intraperitoneal administration of bleomycin for in-
duction of fibrosis. This study showed that thalido-
mide had an inhibitory effect on the synthesis of col-
lagen, TGF-, IL-6, and VEGF; thus, it reduced the
pulmonary fibrosis. In their histopathological evalu-
ations using Azan stains, these researchers reported
an increase in the thickness of the intra-alveolar wall,
as well as infiltration of inflammatory cells and colla-
gen deposition in the interstitial lung tissue in the Bleo
group compared to the Bleo+Thal group 23. In addi-
tion, Zhao et al. (2009) demonstrated that thalido-
mide has a therapeutic effect on lung fibrosis. To
induce lung fibrosis in mice, they administered sub-
cutaneous bleomycin on a daily basis. In the treat-
ment group, oral bleomycin was administered one
week before bleomycin injections. According to their
results, thalidomide could be effective in the treat-
ment of lung fibrosis via its inhibitory effect on hy-
droxyproline (HYP) and -SMA protein 24. Singhal
et al. (1999) demonstrated that the inhibitory effect
of thalidomide on the expression of IL-6 is related
to cell growth and angiogenesis; hence, the drug has
been administered in multiple myeloma 22. Moreover,
it has been reported that thalidomide reduces the
level of TGF-, which is related to cell differentiation,
and shows anti-inflammatory 11, anti-angiogenesis 12
, and immunomodulatory effects 26–28. It seems that
thalidomide can reduce induced lung fibrosis via in-
hibition of angiogenesis, regulation of the immune re-
sponse and proliferation, and its anti-inflammatory
effects. Horton et al. (2012) demonstrated that oral
thalidomide in patients with lung fibrosis could sig-
nificantly alleviate patients’ cough 29. Severe cough
is one of the symptoms of lung fibrosis in patients,
which is resistant to conventional therapies. It is a
disabling symptom, and there are as yet no effective
2978
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Figure3: Histological and immunohistochemicalevaluationsof the lungtissue inBleo+Thalgroupthree.(A)
H&E staining, the image lower interstitial lung tissue thickness (arrows) and a low degree of inflammatory cell
infiltration (arrowheads). Moreover, the number of alveolar and alveolar spaces were increased when compared
to the control group (open arrowheads). (B) Masson’s trichrome staining that blue color in the image indicates
collage deposition areas (arrows). (C) IHC staining shows a decrease of distribution of Cox-2+ cells compared
to the 1st group (arrows). A few of cells with brown cytoplasm that expressing Cox-2 protein was observed in
the lung tissue (arrowheads). In addition, the Cox-2+ cells frequently were observed in alveolar interstitial tissue
(arrows). The images were acquired at the 40X magnification.
treatments for it. It is suggested that thalidomide can
be effective in treating such patients by influencing the
respiratory tract sensory nerves 30,31. In the current
study, the qualitative results of immunohistochemi-
cal evaluations indicated that the distribution of Cox-
2 protein in the Bleo+Thal group was mainly in the
epithelial regions of pulmonary alveoli and respira-
tory bronchioles. Moreover, Cox-2+ cell count using
the morphometric approaches demonstrated that the
number of these cells in the Bleo+Thal group was sig-
nificantly lower than that in the Bleo group (P<0.001).
It was shown in the current study that thalidomide
protects against lung fibrosis by decreasing the num-
ber of Cox-2+ cells. There are few reports in this as-
pect, and the role and expression of Cox-2 in differ-
ent types of lung fibrosis is unknown. Paivaniemi
et al. demonstrated in a study that an increase in
the number of Cox-2-expressing epithelial cells in the
lung tissue is possibly a positive prognostic factor for
inhibition of fibrosis 32. Prostaglandins are generated
from the action of prostaglandin synthases, called cy-
clooxygenases. Cox-2 is the second isoform of Cox,
which is inducible and is expressed following inflam-
mation. The enzyme contributes to the development
of pain, inflammation, and edema. The Cox-2 expres-
sion could be induced by inflammatory stimulants,
cytokines, growth factors, and tumor promoters. This
is while the enzyme is suppressed by steroidal and
non-steroidal anti-inflammatory drugs 33. Vancheri et
al. (2004) demonstrated that in lung fibrosis, fibrob-
lasts are unable to produce Cox-2, thereby having a
defect in the production of prostaglandin E2 34–36. Ad-
ditionally, Keerthisingam et al. (2001) and Xaubet
et al. (2004) reported that the levels of Cox-2 and
prostaglandin E2 in cultured fibroblasts derived from
IPF patients 37,38. However, it is shown that in cancer
thalidomide inhibits lipopolysaccharide-mediated in-
duction of inflammatory factors including Cox-2 and
prostaglandin E2 in a dose-dependentmanner. More-
over, the drug is shown to increase the degradation
of Cox-2 mRNA, which can be helpful in the treat-
ment of the disease 13. Considering the various roles
Cox-2 plays in different diseases and the complexity of
themolecularmechanisms that thalidomide andCox-
2 are involved in, further studies are required in this
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Figure4: Histological and Immunohistochemical analyseson the lung tissue inCMCGroup four.(A) The lung
tissue alveolar has a normal appearance, and no evidence of the congestion and inflammatory cells was observed.
Also, there is no evidence of interstitial tissue remodeling. (B) The results of photomicrographs from Masson’s
trichrome staining. The area involved collagen fibrils, in this regard, with reduced levels of collagen. (C)Cox-2
immunohistochemistry (anti- Cox-2) shows that the number of Cox-2+ cells is not and rarely.
field.
In this work, a significant reduction of connective tis-
sue and a significant increase in alveolar spaces in
the bleomycin thalidomide group compared to the
bleomycin group could indicate a decrease in fibrosis
following thalidomide use.
CONCLUSIONS
Thalidomide decreases the severity of damages in the
lung, increases the number of pulmonary alveoli, and
decreases the amount of connective tissue following
induction of fibrosis, which is probably mediated by
decreasing the expression of Cox-2 protein. As al-
ready mentioned, the thalidomide mechanism of ac-
tion is complex, and there are many unknown aspects
of lung fibrosis. Therefore, administration of thalido-
mide via other routes, as well as the induction of fi-
brosis in other animal models, and other times from
initiation of the fibrosis process would be further in-
vestigated to compare with the results of the current
study.
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